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| INTRODUC TI ON
Measurement of biomarkers before treatment is of importance in the optimum management of patients with colorectal cancer (CRC). For example, tissue-based biomarkers such as RAS mutation, BRAF mutation, HER2 amplification, and microsatellite instability are used to determine prognosis and guide systemic therapy, especially in metastatic CRC. 1, 2 Tissue-based biomarkers have been extensively reviewed in recent years and remain the gold standard at present. However, sampling bias can readily occur in conventional sampling methods such as needle biopsies. 3 This is due to the difficulty of obtaining sufficient material of adequate quality for cancer genome profiling 4, 5 and sampling biases that arise from genetic heterogeneity ( Table 1) . [6] [7] [8] [9] In contrast, a new diagnostic concept referred to as "liquid biopsy" has received considerable attention over the past few years. 10, 11 Compared with a classic biopsy, liquid biopsies are more convenient, and present minimal procedural risk to the patient (Table 1) . 12 Over the past 10 years, large-scale clinical studies have focused on the use of circulating tumor cell (CTC) counts as predictors for prognosis and response to therapy, particularly in breast and prostate cancer. 10, 13 Furthermore, relevant molecular information may also be obtained by analyzing microRNA (miRNA) present in extracellular vesicles or exosomes. 14 Recently, several reports have described the potential utility of management of patients with cancer as a result of advances in circulating tumor DNA (ctDNA) analysis. 8, 10 Thus, in the present review, we focus on the potential clinical utility of ctDNA as key components of liquid biopsies in CRC.
its prognosis has improved because of development of diagnosis and advancement in treatments including surgery and chemotherapy. However, because of intratumor heterogeneity and clonal evolution, tumors often develop resistance to treatment. Genotyping tumor tissue in search of somatic genetic alterations for actionable information has become routine examination in clinical practice.
However, the inherent molecular heterogeneity of metastatic tumors and the ability of cancer genomes to dynamically evolve are not properly captured by tissue specimens only. Circulating tumor DNA (ctDNA) carrying tumor-specific genetic or epigenetic alterations is released into the circulation from tumor cells undergoing apoptosis or necrosis. Analysis of ctDNA has the potential to change clinical practice by exploiting blood rather than tissue, as a source of information. Here, we provide an overview of the characteristics of ctDNA and focus on detection methods for ctDNA, and the feasibility of use of ctDNA to monitor tumor dynamics for patients with colorectal cancer.
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| CIRCUL ATING CELL-FREE DNA AND C TDNA B IOLOGY
Cell-free DNA (cfDNA) was first reported in 1948 by Mandel and Métais who detected non−cell−bound nucleic acids in the bloodstream of individuals with cancer. 15 cfDNA is thought to be released from cells mostly through apoptosis and necrosis. [16] [17] [18] [19] 
| DE VELOPMENT OF APPROACHE S FOR DE TEC TION OF C TDNA
Analysis of ctDNA varies from analysis of a point mutation to wholegenome analyses. Sensitivity of traditional approaches to DNA analysis (such as Sanger sequencing) is insufficient for detection of somatic mutations in plasma cfDNA in patients with cancer. 11 To overcome this limitation, it is essential to develop highly sensitive and reproducible detection methods to identify ctDNA. Methodologies for detecting ctDNA are shown in Table 2 . [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] Digital droplet PCR uses a droplet generator to partition single pieces of DNA into droplets using an oil/water emulsion. 46 Each molecule is individually analyzed for target sequences through an end-point PCR, allowing the detection of mutant or wild-type DNA fragments. This method can detect multiple mutations from the same sample with high sensitivity (from 0.05% to 0.001%), but its multiplexing capabilities are limited to the detection of five to 10 different target sequences. The BEAMing method, first described by Diehl et al, 28 is based on single-molecule PCR on microparticles in water-in-oil emulsions. Sensitivity is approximately 0.01%; however, this method is relatively complex and hardly usable for routine analysis.
Thus, these methods are generally suited to investigate small numbers of mutations and are often applied to analysis of cancer hotspot mutations.
Targeted sequencing can allow the interrogation of multiple loci with high sensitivity using PCR amplicons or hybrid capture methods that suppress background noise. Regions for sequencing range from individual exons of interest (kilobases) to the entire exome (~50 megabases). By reducing the background error rates of sequencing, ctDNA can be detected at allele fractions below 0.1%. 40, 47 Amplicon-based assays that have been optimized for the purpose of ctDNA analysis can target dozens to hundreds of amplicons 42, 47, 48 The sensitivity of ctDNA detection can be further enhanced, even with limited amounts of input material, by using multiplexed patient-specific panels in combination with targeted sequencing methods. 47 However, because the cost for detection of dozens of mutations in cfDNA is still expensive (>900 USD/test), technical development for genotyping and/or a NGS system for ctDNA detection is expected to reduce the cost in the near future.
| REL ATI ON S HIP B E T WEEN CLINI C AL FAC TOR S AND C TDNA IN PATIENTS WITH CRC
To better understand the biology of ctDNA, it is important to consider the relationship between clinicopathological factors and ctDNA. Associations between clinicopathological factors and ctDNA are shown in Table 3 . [49] [50] [51] ctDNA is strongly correlated with initial tumor burden as estimated from the RECIST criteria, 49, 51 suggesting that tumor volume is significantly related to the detection of ctDNA in plasma. Patients with liver metastasis showed significantly higher ctDNA compared to patients without metastasis at this site. 50, 51 In contrast, peritoneal metastasis was not correlated with ctDNA. 50, 51 The relationship between ctDNA and number of metastatic organs is controversial. [49] [50] [51] These data suggest that intrinsic biological characteristics of tumors may impact ctDNA release as well as tumor burden. To further optimize the evaluation of ctDNA analysis, further studies exploring the external factors that may influence the results of ctDNA determination might be needed.
| CLINI C AL RELE VAN CE OF C TDNA FOR ADVAN CED CRC
Circulating tumor DNA analysis can be applied to diagnose, identify and track tumor-specific alterations during the course of the disease, and to guide therapeutic decisions (Figure 1) . In this section, we focus on the significance of ctDNA as a prognostic biomarker, for minimal residual disease and recurrence monitoring and treatment response/resistance (Table 4) .
| Prognostic biomarkers
Patients with detectable ctDNA in their plasma were shown to have worse survival outcomes than those without. 52, 53 Another study showed a strong association between ctDNA positivity and recurrence-free survival (RFS), and overall survival (OS) in patients with CRC irrespective of tumor stage, study size, tumor markers, detection methods, and sample type. 54 A meta-analysis of 1076 patients with mCRC treated with chemotherapy confirmed that baseline total cfDNA levels correlate with OS. 55 The utility of ctDNA and cfDNA as a prognostic parameter and alternative modality for mutation detection before treatment in metastatic CRC (mCRC) was demonstrated in the randomized CORRECT phase III trial. 56 In this trial, 166 mCRC patients received a placebo and 337
were treated with regorafenib. Despite high interpatient variability, high cfDNA concentrations were associated with shorter median OS and progression-free survival (PFS) in both placebo and regorafenib groups. 56 PFS of patients with KRAS mutations in plasma in the regorafenib group was shorter than in those without mutations. 57 The prognostic value of KRAS mutations in plasma but not in tumor tissue was confirmed. 58 Thus, the detection of ctDNA and total cfDNA levels could have strong prognostic value in CRC and is directly related to disease burden. 61 In patients treated with chemotherapy, presence of ctDNA after completion of chemotherapy was also associated with a shorter RFS (P = .001). 61 Another study also reported the ability of ctDNA to detect MRD in patients with locally advanced rectal cancer (T3/T4 and/or nodal metastasis positive) planned for neoadjuvant chemoradiotherapy. 62 Although there was no difference in RFS between patients with detectable ctDNA at baseline (pretreatment) and those without detectable ctDNA, patients with a ctDNA-positive status after chemoradiotherapy or surgery had an increased risk of recurrence (chemoradiotherapy: hazard ratio [HR]
| Minimal residual disease and recurrence monitoring
6.6, P < .001; surgery: HR 13.0, P < 0.001). 62 Estimated 3-year RFS was 33% for patients with postoperative ctDNA positivity and 87%
for those with postoperative ctDNA negativity. These data suggest that postoperative ctDNA detection may be useful for the prediction of recurrence irrespective of the use of adjuvant chemotherapy.
Thus, ctDNA-based screening of patients with a higher risk of relapse may create opportunities for therapeutic intervention before the development of clinical metastasis.
| Treatment response, clonal evolution, and resistance
Serial liquid biopsies may have particular utility in which resistant mutations could be prospectively identified and treatment could be changed in real time. For example, liquid biopsies have been successfully applied to identify mechanisms of resistance for epidermal growth factor (EGFR) inhibitor in mCRC patients. 63 Significant proportions of CRC harbor mutations in KRAS, BRAF, or NRAS that could cause resistance to an EGFR inhibitor, and these hotspot mutations are candidates for mutations detectable in plasma. 55, 58 Previous reports showed that patients with RAS wild-type CRC in tissue, and plasma that is positive for KRAS and BRAF mutations can be resistant to the EGFR inhibitor. 46, [64] [65] [66] Importantly, CRC presumably contain resistant mutant clones before treatment and the proportion of these resistant clones increase under therapeutic pressure. 67 Timecourse analysis of ctDNA showed that several mutations rapidly emerge during EGFR blockades and can often be detected before Furthermore, there was a clear relationship between an increasing bTMB score and PFS. 74 Kim et al 75 also reported concordance of tumor mutational load between tumor tissue and plasma using a 73-gene sequencing panel in metastatic gastric cancer. This analysis showed that there was moderate correlation between tumor plasma mutational load and tumor tissue mutational load (r 2 = 0.54). 75 Furthermore, both overall response rate and PFS in patients treated with anti-PD-1 therapy with a high mutational load score of ctDNA significantly improved compared to patients with a low mutational load score of ctDNA. 75 These data suggest that high bTMB could be a clinically actionable biomarker for anti-PD-1 or anti-PD-L1 therapy as well as high tTMB. As there are few reports on the relationship between tumor mutation burden (both tTMB and bTMB) and clinical benefit of anti-PD-1 or anti-PD-L1 therapy, especially in CRC patients with mismatch repair proficiency, further study will be needed. Moreover, although the
ctDNA application Summary
Prognostic biomarker • Patients with detectable ctDNA in their plasma showed not only worse survival but also shorter progression-free survival than those without it [52] [53] [54] [55] 58, 59 • Baseline total cfDNA levels correlate with overall survival in patients with mCRC treated with chemotherapy 56, 57 Minimal residual disease and recurrence monitoring
• Absence of ctDNA after surgery is associated with a better prognosis and smaller chance of relapse, irrespective of the use of adjuvant chemotherapy [60] [61] [62] [63] Treatment response, clonal evolution, and resistance
• ctDNA enables us to monitor response to treatment repeatedly with minimal invasion [64] [65] [66] [67] • Raised cfDNA concentrations, increase in number of mutations and newly emerged mutations indicate treatment failure and/or evolution of resistance to treatment [64] [65] [66] [67] [68] [69] cfDNA, cell-free DNA; ctDNA, circulating tumor DNA; mCRC, metastatic colorectal cancer.
TA B L E 4 Summary of studies on clinical relevance of ctDNA for colorectal cancer F I G U R E 2 Liquid biopsies to monitor cancer evolution during target therapy. Time-course analysis of tumor-specific mutations in the blood of patients is useful to monitor a response and resistance to molecular targeted drugs. For example, we describe a patient with metastatic colorectal cancer treated with EGFR inhibitor. Circulating tumor DNA allows us to identify, track, and quantify clones bearing distinct alleles. Monitoring truncal mutations (TP53, APC) allow us to track tumor burden whereas lesionspecific mutations (KRAS, BRAF) reflect clonal evolution during chemotherapy. Data of this figure are derived from a combination of our original data with other studies. 32, [64] [65] [66] EGFR, epidermal growth factor receptor; PD, progressive disease; VEGF, vascular endothelial growth factor number of patients with ctDNA detected in advanced cancers is likely to be high, that in early-stage cancers is insufficient. 76, 77 Further technical development for genotyping and/or genome sequencing to increase sensitivity and decrease the false-positive rate is needed to make it possible to detect early cancer using liquid biopsy as a cancer screening test.
In conclusion, we believe that liquid biopsy is likely to be an alternative standard method for monitoring progressive genomic alterations during tumor evolution during exposure to molecular targeted drugs. Liquid biopsy has shown potential utility across a range of applications and will contribute to personalized oncology.
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